DuChemBio Co Ltd (176750)

Currency in KRW
6,440
-140(-2.13%)
Closed·
176750 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6,3206,580
52 wk Range
5,10012,770
Key Statistics
Bid/Ask
6,430.00 / 6,440.00
Prev. Close
6,580
Open
6,570
Day's Range
6,320-6,580
52 wk Range
5,100-12,770
Volume
30.93K
Average Volume (3m)
51.08K
1-Year Change
-35.9204%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
176750 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14,500
Upside
+125.16%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14,500
(+125.16% Upside)

Earnings

Latest Release
Aug 17, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

176750 Income Statement

Compare 176750 to Peers and Sector

Metrics to compare
176750
Peers
Sector
Relationship
P/E Ratio
26.4x2.6x−0.3x
PEG Ratio
−2.390.050.00
Price/Book
3.7x1.2x2.6x
Price / LTM Sales
4.6x2.0x3.1x
Upside (Analyst Target)
125.2%89.2%49.0%
Fair Value Upside
Unlock29.0%6.3%Unlock

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

Employees
126

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
40.69K0.14%267.74M
Other Institutional Investors
14.67M51.75%96.52B
Public Companies & Retail Investors
13.64M48.11%89.72B
Total
28.34M100.00%186.51B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Geo-Young Co., Ltd.51.75%14,669,13096,522,875
Dimensional Fund Advisors LP0.13%38,048250,356

FAQ

What Is the DuChemBio (176750) Stock Price Today?

The DuChemBio stock price today is 6,440 KRW.

What Stock Exchange Does DuChemBio Trade On?

DuChemBio is listed and trades on the KOSDAQ.

What Is the Stock Symbol for DuChemBio?

The stock symbol for DuChemBio is "176750."

What Is the DuChemBio Market Cap?

As of today, DuChemBio market cap is 186.51B KRW.

What Is DuChemBio's Earnings Per Share (TTM)?

The DuChemBio EPS (TTM) is 247.

When Is the Next DuChemBio Earnings Date?

DuChemBio will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is 176750 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has DuChemBio Stock Split?

DuChemBio has split 0 times.

How Many Employees Does DuChemBio Have?

DuChemBio has 126 employees.

What is the current trading status of DuChemBio (176750)?

As of Aug 18, 2026, DuChemBio (176750) is trading at a price of 6,440 KRW, with a previous close of 6,580 KRW. The stock has fluctuated within a day range of 6,320 KRW to 6,580 KRW, while its 52-week range spans from 5,100 KRW to 12,770 KRW.

What Is DuChemBio (176750) Price Target According to Analysts?

The average 12-month price target for DuChemBio is 14,500 KRW, with a high estimate of 14500 KRW and a low estimate of 14500 KRW. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +125.16% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.